The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

The Role Of Tumor Marker CA 15-3 in Detection of Breast Cancer Relapse After Curative Mastectomy

유방암 환자에서 근치적 유방 절제술 후 재발 발견에 대한 CA 15-3의 역할

  • Hyun, In-Young (Department of Nuclear Medicine, Inha University College of Medicine) ;
  • Kim, In-Ho (Department of Internal Medicine, Inha University College of Medicine) ;
  • Lee, Moon-Hee (Department of Internal Medicine, Inha University College of Medicine) ;
  • Kim, Chul-Soo (Department of Internal Medicine, Inha University College of Medicine)
  • 현인영 (인하대학교 병원, 핵의학과) ;
  • 김인호 (인하대학교 병원, 혈액종양 내과) ;
  • 이문희 (인하대학교 병원, 혈액종양 내과) ;
  • 김철수 (인하대학교 병원, 혈액종양 내과)
  • Published : 2004.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The purpose of this study was to determine the utility of tumor marker CA 15-3 in the following: the diagnosis of breast cancer relapse after curative mastectomy, and the differentiation or the value of tumor marker by site of metastases. Materials and Methods: Two hundred two patients (median age 48 years) with breast cancer included in the follow-up after curative mastectomy. The tumor marker CA 15-3 was determined by IRMA (CIS BIO INTERNATIONAL, France). Test values > 30 U/ml were considered elevated (positive). Results: Among 202 patients, recurrent diseases were found in 16 patients. CA 15-3 was elevated in 5 of 16 patients with recurrences. There was no false-positive patient who had elevated CA 15-3. Sensitivity and specificity of CA 15-3 for detection of breast cancer recurrence were 31%, and 100%. CA 15-3 was elevated in all of the 4 patients with liver metastases. CA 15-3 was elevated in none of the patients who relapsed with metastasis to bone-only or contralateral breast-only. Conclusion: The tumor marker CA 15-3 in the detection of breast cancer relapse after curative mastectomy is specific, but not sensitive. However, it is useful to rule out liver metastases of breast cancer, which indicates bad prognosis.

목적 : 유방암 환자에서 근치적 유방 절제술 후 재발의 발견에 대한 CA 15-3의 역할을 평가하고 재발된 환자에서 전이 부위에 따른 CA 15-3의 관계를 비교하였다. 대상 및 방법 : CA 15-3 값이 측정된 환자 중 원발성 유방암으로 근치적 유방 절제술을 시행 받았으며 분석하고자 하는 모든 임상적, 병리학적 인자에 대한 정보가 의무 기록에 기재되고 최소한 3개월간 외래 추적이 가능하였던 202명을 대상으로 분석하였다. CA 15-3은 IRMA 15-3 키트(CIS BIO INTERNATIONAL, France)로 정량적으로 측정하여 정상 상한값을 30 U/ml으로 정하였다. 결과: 근치적 유방 절제술 후 재발을 진단하는 CA 15-3의 진단 성적은 예민도 31%(5/16), 특이도 100%(186/186), 양성 예측도 100%(5/5), 음성 예측도 94%(186/197)이었다. 재발 환자에서 전이 부위에 따른 CA 15-3의 진단 성적을 비교하면 간전이가 관찰된 환자의 CA 15-3값은 모두 상승하여 간전이의 진단에 대한 CA 15-3의 예민도는 100%로 매우 좋았다. 그러나 골전이 또는 국소지역전이만 관찰된 환자의 CA 15-3 값은 정상으로 골전이 또는 국소지역전이의 진단에 대한 CA 15-3 검사는 유용하지 않았다. 결론: 유방암 환자에서 근치적 유방 절제술 후 재발의 발견에 대한 CA 15-3의 진단 성적은 매우 좋은 특이도를 보였으나 예민도는 낮았다. 그러나 비교적 예후가 불량하다고 알려진 간전이로 첫 재발한 환자의 CA 15-3 값은 모두 증가되어 유방암 환자에서 CA 15-3의 측정은 간전이 발견에 매우 유용하였다.

Keywords

References

  1. Ministry of Health and Welfare, Republic of Korea Annual Report of Cancer Registry Programme in the Republic of Korea. (2000.1.1-2000.12.31), 2002
  2. Fisher B, Slack N, Katrych D, Wolmark N: Ten years follow-up results of patients with carcinoma of the breast in a cooperative trial evaluation surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975;140:528-34
  3. O'Rourke TJ: Tumor markers. In; Calabresi P, Schein PS, et al. Medical oncology: basic principles and clinical management of cancer, 2nd ed., pp 163-172, New York, Mcgraw-Hill, inc., 1993
  4. Hayes DF, Zurawski NR, Kufe DW. Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clinic Oncol 1986;4:1542-50 https://doi.org/10.1200/JCO.1986.4.10.1542
  5. ASCO Special Article. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77 https://doi.org/10.1200/JCO.1996.14.10.2843
  6. ASCO Special Article. Recommended breast cancer surveillance guidelines. American Society of Clinical Oncology. J Clin Oncol 1997;15:2149-56
  7. ASCO Special Article. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865-78
  8. Linsley PS, Ochs V, Laska S, Horn D, Ring DB, Frankel AE, et al. Elevated levels of a high molecular weight antigen detected by antibody W1 in sera from breast cancer patients. Cancer Res 1986;46:5444-50
  9. Thompson CH, Jones SL, Whitehead RH, McKenzie IF. A human breast tissue-associated antigen detected by a monoclonal antibody. J Natl Cancer Inst 1983;70:409-19
  10. Moon SD, Jung SS, Kim IC, Lee DS. Comparison of CA 15-3 with CEA as tumor marker of breast cander. J of Korean Cancer Assoc 1992;24:829-33
  11. Kim H, Le YH. CA 15-3 in patients with primary and recurrent breast cancer. J Korean Surg Soc 1995;50:36-41
  12. Jung JH, Park HY, Lee YH. Clinical value of CEA, CA 15-3 and TPS in breast cancer. J Korean Breast Cancer Soc 2001;4:136-43 https://doi.org/10.4048/jkbcs.2001.4.2.136
  13. Cheung KL. Editorial comment on 'Serum markers in breast cancer management' Eur J Cancer 2002;38:1165-6
  14. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, et al. Prognostic role of serum CA 15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 2002;38:1181-8
  15. Kokko R, Holli K, Hakama M. Ca 15-3 in the follow-up of localized breast cancer: a prospective study. Eur J Cancer 2002;38:1189-93 https://doi.org/10.1016/S0959-8049(01)00429-4
  16. Krengli M, Pastore G, Maffei S. The importance of the follow-up in patients operated on for breast cancer. A retrospective analysis of 2482 cases. Minerva Med 1993;84:409-15
  17. Safi F, Kohler I, Rottinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-214
  18. Kim HK, Heo DS, BangY-J, Kim NK. Pattern of recurrence of breast cancer in Korean female patients. J of Korean Cancer Assoc 1999;31:509-16
  19. Kim S-H. Chemotherapy of breast cancer. Kor J Med 2000;58:497-509
  20. Wojtacki J, Kruszewski WJ, Sliwinska M, Kruszewska E, Hajdukiewicz W, Sliwinski W, et al. Elevation of serum CA 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases. Przegl Lek 2001;58:498-503
  21. Buffaz P-D, Gauchez A-S, Caravel J-P, Vuillez J-P, Cura C, Agnius-Delord C, et al. Can tumour marker assays be a guide in the prescription of bone scan for breast and lung cancers? Eur J Nucl Med 1999;26:8-11